Trotta Roberto, Donati Maria Benedetta, Iacoviello Licia
Angela Valenti Laboratory of Genetic and Environmental Risk Factors for Thrombotic Disease, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro, Italy.
Pharmacol Res. 2004 Apr;49(4):351-6. doi: 10.1016/j.phrs.2003.07.018.
With the recent rapid increase in scientific understanding of the human genome it is becoming possible to identify the extent to which genetic variations influence drug response. The emergence of pharmacogenetics heralds a new era in which drug therapies will be selected on the basis of differences in individuals' genotypes, enhancing drug safety and efficacy. The major focus of this review is pharmacogenetics of antihypertensive drugs. Genetics can influence the pharmacokinetics and pharmacodynamics of such drugs at different levels. The presently available applications of genetic concepts to some drugs commonly used in the treatment of hypertension (ACE-inhibitors, diuretics, beta-blockers...) will be summarized. Also sensitivity to salt intake will be considered as an example of pharmacogenetics. The identification of genetic markers of drug response will help to achieve a better control of blood pressure in the population, by allowing a better tailor of antihypertensive therapy to individual patients.
随着近期对人类基因组的科学认识迅速增加,识别基因变异影响药物反应的程度变得越来越可能。药物遗传学的出现预示着一个新时代的到来,在这个时代,药物治疗将根据个体基因型的差异来选择,从而提高药物的安全性和疗效。本综述的主要重点是抗高血压药物的药物遗传学。遗传学可以在不同水平上影响此类药物的药代动力学和药效动力学。将总结目前基因概念在一些常用于治疗高血压的药物(血管紧张素转换酶抑制剂、利尿剂、β受体阻滞剂等)中的应用。对盐摄入的敏感性也将作为药物遗传学的一个例子进行探讨。药物反应基因标记的识别将有助于通过更好地为个体患者量身定制抗高血压治疗,从而在人群中更好地控制血压。